Mobilize Clinical Trial for CIDP
For US Audience Only
MOBILIZE (EFC17236)
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE)
The purpose of this Phase 3 study is to test the effects and safety of riliprubart compared to placebo in adult participants with CIDP for which the usual treatments do not work.
This study uses an investigational medication called riliprubart. The investigational medicine is injected in a vein or under the skin, either at the clinic or at home (self-administered). It blocks a particular part of the body’s defense system from being overactive.
In this study you will have a 50% chance of receiving either a placebo or the investigational medication (riliprubart) initially for 24 weeks (5 ½ months) and then will receive the investigational medication (riliprubart) for the remaining 24 weeks (5 ½ months).
For more information on this Phase 3 study and to complete a pre-screening questionnaire please visit: www.sanofistudies.com/NBRX.
For a list of clinical trial sites https://clinicaltrials.gov/study/NCT06290128.